Browse News
Filter News
Found 18,124 articles
-
The 25th Annual Meeting of the American Society of Gene and Cell Therapy wrapped up on Thursday. BioSpace looks at some of the highlights.
-
CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)
5/20/2022
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for OLUMIANT® (baricitinib) for the treatment of adults with severe alopecia areata (AA).
-
Cortexyme Appoints Dr. Philip Low to Its Board of Directors
5/20/2022
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Dr. Philip S. Low, a renowned targeted drug discovery researcher and veteran biotech entrepreneur, to the company’s Board of Directors.
-
Cortexyme Successfully Completes Acquisition of Novosteo
5/20/2022
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the completion of its acquisition of Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury.
-
BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment Conference
5/20/2022
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference now scheduled for Tuesday, May 24 at 9:00 a.m. ET.
-
Gene Therapy Market Size to Reach US$ 46.5 Billion by 2030
5/20/2022
The global gene therapy market size was valued at US$ 6 billion in 2020 and is projected to reach US$ 46.5 billion by 2030, growing at a CAGR of 22.8% from 2021 to 2030.
-
GeNeuro is developing therapeutics that tackle the viral proteins that potentially contribute to neurodegeneration seen in patients with MS, amyotrophic lateral sclerosis (ALS) and even COVID-19.
-
Voyager Therapeutics’ TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy Programs
5/19/2022
Voyager Therapeutics, Inc. is scheduled to present new preclinical data on a family of AAV9-derived TRACER capsids demonstrating cross-species central nervous system transduction.
-
Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual Meeting
5/19/2022
Athira Pharma, Inc. announced, based on the preliminary vote count provided by its proxy solicitor, that Athira’s shareholders have approved the election of all three of Athira’s highly qualified, independent director nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – to the company’s board of directors.
-
Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022
5/19/2022
Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022.
-
Axsome Therapeutics announced that it published the results of its Ascend Phase-II clinical trial of AXS-05 to treat Major Depressive Disorder in The American Journal of Psychiatry.
-
Possibly reflecting the current Bear market, Berkshire Hathaway has walked away from its stake in both AbbVie and BMS.
-
Cyclo Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
5/18/2022
Cyclo Therapeutics, Inc. announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.
-
Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry
5/18/2022
Axsome Therapeutics, Inc. today announced the publication of the results from the pivotal ASCEND Phase 2 clinical trial of AXS-05 (dextromethorphan-bupropion) in major depressive disorder (MDD).
-
CND Life Sciences Awarded NIH SBIR Grant to Study Novel Skin Biopsy Test for Dementias
5/18/2022
CND Life Sciences, an innovative medical diagnostics company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, has been awarded a $2.4 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH).
-
Seelos Therapeutics Receives a Notice of Allowance in the U.S. for an Additional Patent for SLS-007
5/18/2022
Seelos Therapeutics, Inc. (Nasdaq: SEEL), today announced it has received a Notice of Allowance for U.S. patent application number 16/833,515 from the United States Patent and Trademark Office (USPTO) covering SLS-007 titled: "Structure-Based Peptide Inhibitors of Alpha-Synuclein Aggregation".
-
C2N Diagnostics Introduces P-tau Multi-Analyte Assay for Research Use Only to Advance Alzheimer’s Disease and Brain Health Field
5/18/2022
C2N Diagnostics, a leader in advanced brain health diagnostics that offers the PrecivityAD™ blood test as an aid to Alzheimer’s disease diagnosis, today announced its latest innovative offering for enhancing care in brain health: a high-resolution mass spectrometry-based plasma tau multi-analyte assay (p-tau MAA) for Research Use Only (RUO).
-
Karuna Therapeutics to Host Virtual Event Highlighting Clinical Program for Psychosis in Alzheimer’s Disease
5/18/2022
Karuna Therapeutics, Inc. announced that it will host a virtual event on Wednesday, May 25, 2022, at 8:00 a.m. ET.
-
INmune Bio, Inc. to Present at the H.C. Wainwright Global Hybrid Investment Conference on May 24th
5/18/2022
INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that harness the patient’s immune system to fight disease, announced today that David Moss, Chief Financial Officer will present a corporate overview at the H.C. Wainwright Global Hybrid Investment Conference.
-
Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder
5/17/2022
Alzamend Neuro, Inc. today announced that it has submitted a Pre-IND (investigational new drug) meeting request for AL001 and supporting briefing documents to the U.S. Food and Drug Administration (“FDA”) for the treatment of bipolar disorder, major depressive disorder and post-traumatic stress disorder (“PTSD”).